David Amran, MD
Allergy & Immunology · Sugar Land, TXNPI 1841294261
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,125 of the $109,267 with a category attached, or 78.8%. GSK accounts for 67.3% of it on its own, with 46 other manufacturers making up the rest. Reporting peaked in 2021 at $34,344 and has fallen 55.1% since, to $15,421 in 2025. Among allergy & immunology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,073 payments — averaging $101.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$74K
- AstraZeneca$15K
- Novartis$5K
- Regeneron Healthcare Solutions, Inc.$3K
- Sanofi$2K
- Pfizer$815
- plus $9K from 41 others
Across 12 payments — averaging $680.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$8K
What the payments were for
- Speaking & faculty fees$86,12579%
- Travel & lodging$1,8502%
- Food & beverage$20,53619%
- Education$7561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$109,267 in reported general payments places this provider in the 95th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 31 | $154,186 |
| XolairOmalizumab | 61 | $147,658 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 19 | $141,583 |
| NucalaMepolizumab | 29 | $107,884 |
| SymbicortBudesonide/Formoterol Fumarate | 68 | $24,112 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $22,868 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $14,127 |
| Arnuity ElliptaFluticasone Furoate | 31 | $7,900 |
| Epinephrine | 54 | $7,792 |
| BreynaBudesonide/Formoterol Fumarate | 43 | $6,116 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,905 |
| Qvar RedihalerBeclomethasone Dipropionate | 21 | $5,507 |
| DuleraMometasone/Formoterol | 11 | $4,123 |
| Pulmicort FlexhalerBudesonide | 16 | $3,565 |
| Montelukast Sodium | 190 | $2,663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $73,512 | $152,779122 claims |
| Grifols USA, LLCGamunex-C | $645 | $141,58319 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $15,161 | $27,67784 claims |
| Hikma Pharmaceuticals USAEpinephrine | $40 | $7,79254 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $350 | $5,50721 claims |
| MerckDulera | $20 | $4,12311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Sugar Land
- Meng ChenSugar Land$42K
- Nerissa D'silvaSugar Land$31K
- John KelleySugar Land$24K
- Vikas KancherlaSugar Land$21K
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.